|
Getting your Trinity Audio player ready...
|
The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics Inc. (GBT), has awarded grants of approximately $50,000 each to five community-based organizations (CBOs) — including one from Miami — as recipients of the inaugural Access to Care Empowerment for Sickle Cell (ACE) Grant Program.
Through the ACE Grant Program, The GBT Foundation plans to fund up to $250,000 per year to support initiatives dedicated to advancing health equity and enhancing education, empowerment, and access to care for people living with sickle cell disease (SCD).
Advancing Sickle Cell Advocacy Project Inc. Project COPE helps children and families navigate their SCD journey by providing peer support, education, mindfulness training, and effective stress-coping techniques.
“CBOs can play an important role as local resources for sickle cell disease patients and caregivers as they navigate their healthcare journey. The GBT Foundation is proud to provide much-needed support to these organizations through the ACE Grant Program, strengthening the potential to create meaningful and sustainable change,” said Jung E. Choi, board member of The GBT Foundation and chief business and strategy officer and head of patient advocacy and government affairs at GBT. “Helping families and caregivers to better support sickle cell warriors and enhance education initiatives for young adults with SCD are important steps to connect them with the high-quality health services they deserve.”
Established in 2021, The GBT Foundation is a community-focused, charitable entity that is committed to improving health equity worldwide, particularly for people living with SCD.
The 2022 ACE
ACE Grant Program recipients were selected by a panel of external and internal experts. Criteria for selection included the programs’ potential impact on SCD patient care, evaluation and sustainability plans, organizational capabilities, and alignment with mission of The GBT Foundation.
The ACE Grant Program builds on the Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program, which is in its fourth year. The ACCEL Grant Program plans to provide up to $500,000 this year to U.S.-based nonprofit healthcare organizations or institutions that serve patients with SCD and their families and seek to improve their access to high-quality healthcare. Since 2019, the ACE and ACCEL programs have granted a total of nearly $1.25 million to 24 organizations to accelerate the development of sustainable and innovative programs for SCD patients.
